Lipoatrophy, a complication of long-term subcutaneous insulin administration, can lead to insulin accumulation at the atrophic site and disruption of normal insulin action rhythms, contributing to both hypoglycemia and postprandial hyperglycemia in EIAS patients.(10). The gene discussed is INS; the disease is Hypoglycemia.